Advertisement

Topics

Domain Therapeutics creates new company to stop Parkinson’s disease progression

06:46 EDT 19 Oct 2016 | Pharmaceutical Business Review

France-based biopharmaceutical firm Domain Therapeutics has established a new company, Mavalon Therapeutics, dedicated to develop a drug candidate to stop the progression of Parkinson’s disease.

Original Article: Domain Therapeutics creates new company to stop Parkinson’s disease progression

NEXT ARTICLE

More From BioPortfolio on "Domain Therapeutics creates new company to stop Parkinson’s disease progression"

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...